On November 13, 2026, the clinical trial registry listed an update for a Phase 3 study of retatrutide. The trial, known as TRANSCEND-T2D-3, is registered under identifier NCT06297603. Its full title is "Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor."
The study is designed to compare retatrutide with placebo in people with type 2 diabetes who also have moderate or severe renal impairment. Enrolled participants have inadequate glycemic control while on basal insulin, with or without background metformin and/or an SGLT2 inhibitor.
According to the registry, the current status of this Phase 3 trial is active, not recruiting. This designation means the study is ongoing and that participant enrollment is not currently open. No results have been posted for this trial as of this update, and no efficacy or safety outcomes are included in this record.
Readers can find more background on this compound by consulting the retatrutide overview page.